Artículos por temáticas

Measurement properties of the German version of the Cambridge examination for mental disorders of older people with Down syndrome and others with intellectual disabilities (CAMDEX-DS)

Loosli SV, Neumann LC, Wlasich E, Prix C, Koll L, Weidinger E, Vöglein J, Wagemann O, Danek A, Nübling G, Levin J.

J Intellect Dev Disabil. 2024 Dec;49(4):402-414. doi: 10.3109/13668250.2024.2317794. Epub 2024 Feb 29.

Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review

Parrotta I, Cacciatore S, D'Andrea F, D'Anna M, Giancaterino G, Lazzaro G, Arcara G, Manzo N.

Neurol Sci. 2024 Apr;45(4):1343-1376. doi: 10.1007/s10072-023-07197-7. Epub 2023 Nov 28.

Current Updates on the Role of MicroRNA in the Diagnosis and Treatment of Neurodegenerative Diseases

Saleem A, Javed M, Akhtar MF, Sharif A, Akhtar B, Naveed M, Saleem U, Baig MMFA, Zubair HM, Bin Emran T, Saleem M, Ashraf GM.

Curr Gene Ther. 2024;24(2):122-134. doi: 10.2174/0115665232261931231006103234.

Psychosocial implications of learning amyloid PET results in an observational cohort

Clark LR, Erickson CM, Chin NA, Basche KE, Ketchum FB, Rosario HL, Peterson AJ, Eveler ML, Johnson SC.

Alzheimers Dement. 2024 Sep;20(9):6579-6589. doi: 10.1002/alz.14153. Epub 2024 Aug 11.

Prodromes in demyelinating disorders, amyotrophic lateral sclerosis, Parkinson disease, and Alzheimer's dementia

Marrie RA, Maxwell CJ, Rotstein DL, Tsai CC, Tremlett H.

Rev Neurol (Paris). 2024 Mar;180(3):125-140. doi: 10.1016/j.neurol.2023.07.002. Epub 2023 Aug 9.

Practicalities (and real-life experiences) of dementia in adults with Down syndrome

Harisinghani A, Cottrell C, Donelan K, Lam AD, Pulsifer M, Santoro SL.

Am J Med Genet C Semin Med Genet. 2024 Dec;196(4):e32098. doi: 10.1002/ajmg.c.32098. Epub 2024 Jul 5.

[Olfaction and Alzheimer's disease: from deficits to therapeutic hopes]

Lopis D.

Geriatr Psychol Neuropsychiatr Vieil. 2024 Dec 1;22(4):394-404. doi: 10.1684/pnv.2024.1197.

The potential roles of salivary biomarkers in neurodegenerative diseases

Jiao LL, Dong HL, Liu MM, Wu PL, Cao Y, Zhang Y, Gao FG, Zhu HY.

Neurobiol Dis. 2024 Apr;193:106442. doi: 10.1016/j.nbd.2024.106442. Epub 2024 Feb 19.

Re: Shahim et al., 2024 "Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction"

Tamborska AA, Bray CF, Kurth T.

Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):476-477. doi: 10.1093/ehjcvp/pvae041.

Prevalence of Concomitant Pathologies in Parkinson's Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms

Walker L, Attems J.

J Parkinsons Dis. 2024;14(1):35-52. doi: 10.3233/JPD-230154.

Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease

Shi J, Touchon J, Middleton LT, Rovira MB, Vassar R, Vellas B, Shen Y.

Sci Bull (Beijing). 2024 Dec 15;69(23):3777-3784. doi: 10.1016/j.scib.2024.09.042. Epub 2024 Sep 28.

[Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease]

Blennow K, Hansson O.

Lakartidningen. 2024 May 31;121:23150.

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy

Li YB, Fu Q, Guo M, Du Y, Chen Y, Cheng Y.

Transl Psychiatry. 2024 Sep 10;14(1):367. doi: 10.1038/s41398-024-03075-8.

Advancement in Analytical Techniques for Determining the Activity of β-Site Amyloid Precursor Protein Cleaving Enzyme 1

Fan J, Wei X, Dong H, Zhang Y, Zhou Y, Xu M, Xiao G.

Crit Rev Anal Chem. 2024;54(6):1797-1809. doi: 10.1080/10408347.2022.2132812. Epub 2022 Oct 13.

Increased molar ratio of free fatty acids to albumin in blood as cause and early biomarker for the development of cataracts and Alzheimer's disease

Glaesser D, Iwig M.

Exp Eye Res. 2024 Jun;243:109888. doi: 10.1016/j.exer.2024.109888. Epub 2024 Apr 6.